Here are the 10-K annual reports from Kiniksa Pharmaceuticals International, plc (KNSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KNSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KNSA filings page.
Kiniksa Pharmaceuticals International, plc reports its annual business overview, highlighting a commercial rare-disease franchise and a focused cardiovascular pipeline. The company markets ARCALYST, an IL‑1α/IL‑1β cytokine trap, as the first and only FDA‑approved therapy for recurrent pericarditis, targeting an estimated 40,000 treated patients in the United States.
Kiniksa is advancing KPL‑387, an IL‑1 receptor monoclonal antibody with FDA Orphan Drug Designation for pericarditis, through a Phase 2/3 recurrent pericarditis program, with Phase 2 data expected in the second half of 2026. Preclinical KPL‑1161 aims for quarterly dosing, while development of abiprubart in Sjögren’s Disease has been discontinued as the company explores strategic options for the asset.
The business model combines internal development with partnerships. Kiniksa evenly splits ARCALYST profits and certain proceeds with Regeneron, has out‑licensed vixarelimab to Genentech with potential milestones and royalties, and granted Huadong rights to ARCALYST in a broad Asia‑Pacific territory. Intellectual property protection extends across composition, methods of use and formulations, supplemented by U.S. and EU regulatory exclusivities.